Rechercher un essai clinique
Autre(s) option(s) de recherche
84 Résultat(s)
Essai en cours de recrutement = ; Essai en cours =
; Essai terminé =
; Financé par un membre IRDiRC =
; Membre d'un ERN =
Essai(s) clinique(s) national(aux)

Berlin
BERLIN

DSHNHL 2008-R6: Salvage therapy of progressive and relapsed aggressive Non-Hodgkin-Lymphoma by combination of Lenalidomide (Revlimid®) with Rituximab, Dexamethason, high-dose ARA-C and Cisplatinum (R2-DHAP): Open-label, multicentre phase I/II study
HELIOS Klinikum Berlin-Buch
Fachbereich für Hämatologie und Stammzelltransplantation

Berlin
BERLIN

ASTRAL: A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma
HELIOS Klinikum Berlin-Buch
Fachbereich für Hämatologie und Stammzelltransplantation

Nordrhein-Westfalen
KÖLN

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART2019.1 in Patients With Relapsed or Resistant CD20 and CD19 Positive B-NHL
Universitätsklinikum Köln
Klinik I für Innere Medizin

Saarland
HOMBURG
DSHNHL 2004-3 (UNFOLDER 21/14 Study): Phase III randomized study of immunochemotherapy Rituximab-CHOP with or without radiotherapy in patients with aggressive, B-Cell Non-Hodgkin's Lymphoma
Universitätsklinikum des Saarlandes
Klinik für Innere Medizin I

Saarland
HOMBURG
DSHNHL 2004-2 (FLYER): Randomized Phase III Study: 6 x anti-CD20-antibody Rituximab + 6 x CHOP-21 vs. 6 x anti-CD20-antibody Rituximab + 4 x CHOP-21 in patients aged 18-60 years with aggressive CD20 positive B-Cell Lymphoma - DE
Universitätsklinikum des Saarlandes
Klinik für Innere Medizin I

Victoria
ADDRESS: NOT PROVIDED - AU
A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms -AU
Institution: Information not provided - AU

WIEN
WIEN
A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde

ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE

Etude randomisée en ouvert évaluant la sécurité d'emploi et l'efficacité de l'ibrutinib chez des patients enfants et jeunes adultes atteints d'un lymphome non hodgkinien à cellules B matures en rechute ou réfractaire - BE
Institution: Information not provided - BE

VLAAMS BRABANT
LEUVEN
HOVON 130 NHL: A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U- BE
UZ Leuven - Campus Gasthuisberg
Department of Hematology

Québec
ADDRESS: NOT PROVIDED - CA
A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms -CA
Institution: Information not provided - CA

Cataluña
BADALONA

BURKIMAB-14: Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica

Madrid
ADDRESS: NOT PROVIDED - ES

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - ES
Institution: Information not provided - ES

Washington
ADDRESS: NOT PROVIDED - US
Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma -GB
Institution: Information not provided - US

ISRAEL
ADDRESS: NOT PROVIDED - IL
A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms -IL
Institution: Information not provided - IL

LOMBARDIA
MILANO

(CARMEN): Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma
IRCCS Ospedale San Raffaele
Dipartimento di Oncologia

Greater London
LONDON
CARPALL: Immunotherapy With CD19 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies
GOSH NHS Foundatin Trust
Great Ormond Street Hospital

Suisse Italienne
BELLINZONA

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts
Ospedale Regionale di Bellinzona e Valli
Unità di Ricerca Clinica in Oncologia - Istituto Oncologico della Svizzera Italiana

Nordrhein-Westfalen
MÜNSTER

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) -DE-
Universitätsklinikum Münster
Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie

SALZBURG
SALZBURG

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Kinder- und Jugendheilkunde

STEIERMARK
GRAZ

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT
Medizinische Universität Graz
Klinische Abteilung für pädiatrische Hämato-Onkologie

TIROL
INNSBRUCK

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT
Medizinische Universität Innsbruck
Pädiatrie I

WIEN
ADDRESS: NOT PROVIDED - AT

BIANCA: A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

BELINDA: Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial - AT
Institution: Information not provided - AT

WIEN
WIEN
A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie

WIEN
WIEN

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde

Zuid-Holland
ROTTERDAM

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - NL
Erasmus MC - Erasmus Medisch Centrum
Polikliniek Kinderhematologie

Suisse Romande
ADDRESS: NOT PROVIDED - CH
B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - CH
Institution: Information not provided - CH

Suisse Romande
ADDRESS: NOT PROVIDED - CH
BELINDA: Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial - CH
Institution: Information not provided - CH

Nordrhein-Westfalen
KÖLN

A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies - DE
Universitätsklinikum Köln
Klinik I für Innere Medizin

Nordrhein-Westfalen
MÜNSTER

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies
Universitätsklinikum Münster
Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie

WIEN
ADDRESS: NOT PROVIDED - AT


A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma - AT
Institution: Information not provided - AT

Québec
ADDRESS: NOT PROVIDED - CA

ELM-2: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma -CA
Institution: Information not provided - CA

Madrid
ADDRESS: NOT PROVIDED - ES

CARBON: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an anti-CD20 x anti- CD3 bispecific monoclonal antibody, and REGN2810, an anti-programmed death-1 (PD-1) monoclonal antibody, in Patients with B-cell Malignancies - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

Parsaclisib Rollover study: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) - ES
Institution: Information not provided - ES

Madrid
MADRID
A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies - ES
Hospital Universitario 12 de Octubre
Unidad de Ensayos Clínicos de Fase Temprana en Hematología

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
ROMULUS: Etude randomisée de phase II évaluant le polatuzumab vedotin ou le pinatuzumab vedotin associés au rituximab chez des patients atteints de lymphome non hodgkinien récidivant/réfractaire - FR
Institution: Information not provided - FR

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

ELM-2 : Étude en ouvert évaluant l'activité antitumorale et la tolérance de REGN1979, un anticorps bispécifique anti-CD20 x anti-CD3, chez les patients atteints d'un lymphome non hodgkinien à cellules B récidivant ou réfractaire -FR
Institution: Information not provided - FR

BRETAGNE
RENNES

Étude de phase 1, évaluant le PF-05082566 en monothérapie chez des patients ayant un cancer en stade avancé, et en association avec rituximab chez des patients ayant un lymphome non hodgkinien (LNH) - FR
CHU de Rennes - Hôpital Pontchaillou
Service d'hématologie clinique

EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies - IT
Institution: Information not provided - IT

Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie

Greater London
ADDRESS: NOT PROVIDED - GB

ELM-2: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma -GB
Institution: Information not provided - GB

Greater Manchester
ADDRESS: NOT PROVIDED - UK
An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies - GB
Institution: Information not provided - UK

Baden-Württemberg
HEIDELBERG

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Deutsches Krebsforschungszentrum
Klinische Kooperationseinheit Pädiatrische Onkologie

Bayern
REGENSBURG

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Regensburg
Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation

Bayern
WÜRZBURG

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Würzburg

Berlin
ADDRESS: NOT PROVIDED - DE

PIVOT IO 020: Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies - DE
Institution: Information not provided - DE

Berlin
BERLIN

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Charité - Universitätsmedizin Berlin

Nordrhein-Westfalen
ESSEN

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

Nordrhein-Westfalen
MÜNSTER

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Münster

Sachsen
LEIPZIG

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

Etude clinique de phase I/IIa évaluant des administrations intra-tumorales (IT) répétées de BT-001 (TG6030) seul ou en combinaison avec le pembrolizumab chez des patients présentant des lésions tumorales cutanées ou sous-cutanées ou des ganglions lymphatiques facilement injectables de tumeurs solides avancées ou métastatiques - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service d'oncologie médicale

Madrid
ADDRESS: NOT PROVIDED - ES
UNITY: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin' s Lymphoma - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) - ES
Institution: Information not provided - ES

ILE-DE-FRANCE
VILLEJUIF

Étude de phase I/II d'escalade de dose de l'inhibiteur d'Histone déacétylase S 78454 administré par voie orale dans la maladie de Hodgkin, les Lymphomes malins non-Hodgkiniens, et les Leucémies Lymphoïdes Chroniques
CLCC Institut Gustave Roussy
Département d'hématologie

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid®) With Rituximab in Subjets With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma (Phase II) - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes

EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR alfa-beta+ T cells in pediatric patients affected by hematological disorders
Institution: Information not provided - IT

LOMBARDIA
ROZZANO

A Phase II Prospective Study of High-dose Myeloablative Therapy, With Stem Cell Devices Support in Elderly Patients (>65 and <75 Years) With Relapsed Aggressive Non-Hodgkin Lymphoma or Resistant to First Line Therapy
IRCCS Istituto Clinico Humanitas
U.O. Oncologia Medica ed Ematologia

PIEMONTE
TORINO

Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette
S.C. di Ematologia

Cambridgeshire
CAMBRIDGE

UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma -GB
Addenbrooke's Hospital
Cambridge Cancer Trials Centre

Greater London
LONDON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust
Great Ormond Street Hospital

Greater London
LONDON
UK Haplo v1.0: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
Guy's Hospital
Department of Haematology

Greater London
UXBRIDGE

Suisse Italienne
BELLINZONA

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - BRUIN - CH
Ospedale Regionale di Bellinzona e Valli

WIEN
ADDRESS: NOT PROVIDED - AT
COVID-19: A Phase 3, open-label, parallel group, multicenter clinical study to evaluate the safety, reactogenicity, and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in participants 45 years or older with either a solid tumor or hematologic malignant disease who are receiving or scheduled to receive systemic anticancer therapy (independent of intent) - AT
Institution: Information not provided - AT

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

Étude ouverte de phase I/II visant à évaluer la pharmacocinétique, la pharmacodynamique, la sécurité d'utilisation et l'activité anticancéreuse de l'Avelumab chez des sujets pédiatriques de la naissance à moins de 18 ans d'âge, atteints de tumeurs solides ou d'un lymphome réfractaires ou en rechute - BE
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Programme d'extension à long terme du Sorafénib - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique

LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
Essai(s) clinique(s) multinational(aux)

Washington
ADDRESS: NOT PROVIDED - US
Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms
Institution: Information not provided - US

Zuid-Holland
ROTTERDAM
A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
Erasmus MC - Erasmus Medisch Centrum

ILE-DE-FRANCE
PARIS

Surrey
GUILDFORD
An Open-Label, Multi-Center Phase I/IIa Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphomas
Ergomed Clinical Research Limited

Washington
ADDRESS: NOT PROVIDED - US
A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
SELINDA: A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
ELM-2: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Institution: Information not provided - US

Suisse Alémanique
BASEL
An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma (Phase II) (coordination)
Hoffmann-La Roche
Hoffmann - La Roche Ltd.

Suisse Alémanique
BASEL
A Multicenter, Open-Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalating Doses of RO7082859 as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab (Gazyva /Gazyvaro) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Hoffmann - La Roche Ltd.

Madrid
COLMENAR VIEJO
A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (coordination)
PharmaMar S.A.
Pharma Mar S.A.

New Jersey
SUMMIT

Texas
HOUSTON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.

Washington
ADDRESS: NOT PROVIDED - US
A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Institution: Information not provided - US

Madrid
COLMENAR VIEJO